Abbott Laboratories Corporation

Other

Abbvie Inc.

Michael D Meyer

William A Carroll

Kevin B Sippy

Robert J Altenbach

Karin Rosemarie Tietje

James F Kerwin

Irene I Drizin

Fatima Z Basha

Michael J Dart

John F DeBernardis

Michael D Wendt

Suzanne A Lebold

Edmund L Lee

Xueqing Wang

Jennifer M Frost

Jerome F Daanen

Diane M Yamamoto

Laurie McCarthy-Meyer

Biswanath De

John K Pratt

Tao Guo

Lijuan Jane Wang

Anthony Ralph Haight

Teodozyj Kolasa

Michael R Schrimpf

Meena V Patel

William H Bunnelle

Jeffrey J Rohde

Richard J Perner

David M Stout

Mark W Holladay

Keith Brian Ryther

Richard B Toupence

Paul P Ehrlich

Chi-nung W Hsiao

Yvonne Connolly Martin

Rajnandan N Prasad

John W Kebabian

Robert W Schoenleber

Jennifer M Pace

Michael P DeNinno

Weijiang Zhang

Albert Khilevich

Robert Guo Ping Wei

Tedozyi Kolasa

Jeffrey W Ralston

Stanley DiDomenico, Jr

William A Caroll

Steven W Elmore

Daniela Barlocco Cristina

Jesse Home

A cantilevered bridge for resonators to permit greater sound production from small sound producing instruments, including a sound producing instrument having an instrument body; a cantilevered bridge lever arm having a first surface and a second surface, with a primary resonator coupled by a biscuit bridge to the first surface of the cantilevered bridge lever arm, and a secondary resonator coupled by a connector to the second surface of the cantilevered bridge lever arm. In a second embodiment, a hinge attachment anchors the cantilevered bridge lever arm to a pivot point within the sound producing instrument.

Cantilevered bridge for resonators

A bumper panel for preventing opening car doors from being damaged from hitting other objects has a design that can be interchanged. The bumper panel may have a design cover that slips over the rigid panel portion having resilient material layer over a rigid panel. The design cover may have an open end to enable the cover to slip over the rigid panel portion and may have mount apertures that align with mount fixtures when configured over the rigid panel. A design cover may be reversible and may have different designs on the inside various sides and surfaces of the design cover. As many as four designs may be displayed depending on the orientation and configuration of the design cover over the rigid panel. A bumper panel may be suspended from mount fixtures or retained along a wall or other object by mount brackets.

Covered bumper panel

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R, R, and Rare as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Chemokine receptor antagonists

The present invention relates to compounds of formula (I) wherein A, E, L, R, R, Rand Rare as defined in the herein, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Compounds as cannabinoid receptor ligands

The present invention provides novel compounds of Formula (I) which are CBselective ligands useful for the treatment of pain.

Indoles are cannabinoid receptor ligands

Compounds of formula I: or pharmaceutically acceptable salts thereof, are useful for controlling synaptic transmission in mammals.

Diazabicyclic CNS active agents

Imidazoles and related compounds as &agr;1A agonists

Compounds of Formula I and II and their pharmaceutically acceptable, salts, esters and prodrugs thereof are selective alpha-1D adrenoceptor anatagonists and may be useful for treating disease states.

Piperazinyl pyrimidine dione compounds selective for adrenoceptors

Compounds of Formula I ##STR1## and II and their pharmaceutically acceptable, salts, esters and prodrugs thereof are selective alpha-1D adrenoceptor anatagonists and may be useful for treating disease states, such as benign prostatic hyperplasia, detrusor insatbility, and incontinence.

Compounds having the formula are .alpha..sub.1 adrenoreceptor antagonists. Processes for making these compounds, synthetic intermediates employed in these processes and a method for inhibiting .alpha..sub.1 adrenoreceptors and treating benign prostatic hyperplasia (also called benign prostatic hypertrophy or BPH) and other urological diseases such as BOO (bladder outlet obstruction), neurogenic bladder and gynecological syndromes such as dysmenorrhea are disclosed.

3-phenylpyrrolidine alpha-1 adrenergic compounds

The present invention relates to a compound of the formula and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and treating BPH.

Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic compounds

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and tr

Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adenergic compounds

The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

Bicyclic substituted hexahydrobenz �e! isoindole alpha-1 adrenergic

Growing community of inventors

Lake Villa, IL, United States of America

Michael D Meyer